Clarametyx Biosciences

Clarametyx Biosciences develops targeted, immune-enabling biologic therapies to counter persistent infections associated with biofilms. Their lead therapeutic candidate, CMTX-101, aims to combat infection by targeting and removing universal structural elements within the bacterial biofilm, making bacteria vulnerable to immune or antibiotic intervention. The company is evaluating its technology in therapeutic and preventive settings to address antibiotic resistance.

Buy Funded Startups lists

Funding Round: Series A

Funding Amount: $33M

Date: 05-Jan-2024

Investors: Ohio Innovation Fund, Nationwide Children’s Hospital, Rev1 Ventures, JobsOhio Growth Capital, C Bio Investors, 1776 Fund

Markets: Biotechnology, Healthtech, Infectious Disease, Health Care, Medical, Pharmaceutical

HQ: Columbus, Ohio, United States

Founded: 2020

Website: https://clarametyx.com/

LinkedIn: https://www.linkedin.com/company/clarametyx-biosciences/

Twitter:

Instagram: